Skip to content

Study · Not a test of the peptide alone · 2005

5 results

Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine.

Banks MR, Farthing MJ, Robberecht P, Burleigh DE

British journal of pharmacology1 Apr 2005Cited by 37 (Europe PMC)

PMID15711593 (opens in a new tab)PMCIDPMC1576079 (opens in a new tab)DOI10.1038/sj.bjp.0706128 (opens in a new tab)PepBankPUB-15711593
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In perfused rat jejunum in vivo, PG 97-269 abolished the effects of VIP on fluid and electrolyte transport.

    In plain wordsIn rats, PG 97-269 stopped the effects of VIP on fluid and salt movement in the gut.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP effects on fluid and electrolyte transport
    Study

    ratn: not reported in source

    perfused rat jejunum in vivo
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    In perfused rat jejunum, PG 97-269 abolished the effects of VIP on fluid and electrolyte transport
    1 context sentence
    Summary · context
    Monolayers of the human colonic cell line (T84) and muscle-stripped preparations of rat jejunum and human ileum were set up in Ussing chambers for recording of transepithelial resistance and short-circuit current.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In perfused rat jejunum in vivo, PG 97-269 attenuated net fluid and electrolyte secretion induced by cholera toxin and E. coli heat labile toxin.

    In plain wordsIn rats, PG 97-269 reduced gut fluid loss caused by cholera toxin and an E. coli toxin.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseEnterotoxin-induced net fluid and electrolyte secretion
    Study

    ratn: not reported in source

    perfused rat jejunum in vivo
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    attenuated cholera toxin and Escherichia coli heat labile toxin-induced net fluid and electrolyte secretion.
    1 context sentence
    Summary · context
    Monolayers of the human colonic cell line (T84) and muscle-stripped preparations of rat jejunum and human ileum were set up in Ussing chambers for recording of transepithelial resistance and short-circuit current.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism

    In rat jejunum and human ileum tissue, PG 97-269 inhibited the responses to VIP.

    In plain wordsIn lab tests on rat and human gut tissue, PG 97-269 reduced the response to VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP-induced secretory responses
    Study

    rat and humann: not reported in source

    muscle-stripped rat jejunum and human ileum in Ussing chambers
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    In rat jejunum and human ileum, responses to VIP were inhibited
    1 context sentence
    Summary · context
    Monolayers of the human colonic cell line (T84) and muscle-stripped preparations of rat jejunum and human ileum were set up in Ussing chambers for recording of transepithelial resistance and short-circuit current.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism

    In rat jejunum tissue, PG 97-269 inhibited responses to electrical stimulation of mucosal neurons.

    In plain wordsIn lab tests on rat gut tissue, PG 97-269 reduced the response to nerve stimulation.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseResponse to electrical stimulation of mucosal neurons
    Study

    ratn: not reported in source

    muscle-stripped rat jejunum in Ussing chambers
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    as were responses of rat jejunum to electrical stimulation of mucosal neurons.
    1 context sentence
    Summary · context
    Monolayers of the human colonic cell line (T84) and muscle-stripped preparations of rat jejunum and human ileum were set up in Ussing chambers for recording of transepithelial resistance and short-circuit current.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In T84 human colonic cell monolayers, the antagonist PG 97-269 competitively antagonised the effect of VIP.

    In plain wordsIn lab-grown human gut cells, a drug called PG 97-269 blocked the action of VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP antagonism in T84 monolayers
    Study

    humann: not reported in source

    T84 human colonic cell monolayers
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    PG 97-269 competitively antagonised VIP in T84 monolayers.
    1 context sentence
    Summary · context
    Monolayers of the human colonic cell line (T84) and muscle-stripped preparations of rat jejunum and human ileum were set up in Ussing chambers for recording of transepithelial resistance and short-circuit current.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.